Mucosal route induces both localized and systemic immunity
Intravacc is currently developing 3 OMV-based intranasal vaccines
Article published in peer-reviewed journal ‘Current Opinions in Immunology’

BILTHOVEN, Netherlands, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Intravacc, a leading Contract Development and Manufacturing Organization (CDMO) specializing in translational research and the development of preventive and therapeutic vaccines, has announced the publication of a review on the efficacy of intranasally administered outer membrane vesicle (OMV)-based vaccines. The paper presents promising results in combatting various emerging and potentially fatal infectious diseases that infiltrate mucosal tissues, such as the oral, nasal, and urogenital surfaces. The review article has been published in the peer-reviewed journal ‘Current Opinion in Immunology' Volume 84, 2023.

Dr. Peter van der Ley, senior scientist of Intravacc and lead author, stated:

“Our review showcases OMVs' potential in mucosal immunization. They prompt robust local and distant immune responses. This offers a new angle for battling infectious diseases."

The review article highlights OMVs, released from Gram-negative bacteria, as promising vaccine candidates. They can carry diverse antigens, including those from viruses and bacteria, making them a versatile vaccine platform, especially when administered intranasally. By targeting the mucosal route, vaccines can induce both localized and systemic immunity. The findings, backed by animal trials, demonstrate OMV-based vaccines' efficacy against various pathogens. They also stress the safety and feasibility of intranasal delivery as an alternative to needles. The review points to ongoing clinical trials. OMV-based vaccines fuel optimism for innovative vaccine strategies that tap into mucosal immunity’s untapped potential.

Dr. Jan Groen, Intravacc’s CEO, says:

“As a CDMO, we are presently developing three OMV-based intranasal vaccines to address bacterial and viral infections for diverse customers. This illustrates the extensive potential of our OMV platform technology, which can also be harnessed for therapeutic vaccines, including those for cancer.”

About Intravacc’s OMV platform technology

For the development of vaccines, Intravacc has designed and developed a platform based on OMVs - spherical particles with intrinsic immune-stimulating properties. The OMVs can be designed with immunogenic peptides and/or proteins that stimulate effective adaptive immunity. The OMV carrier has been optimized to induce a more effective immune response against these newly introduced antigens. Intravacc has also developed genetic tools to increase the yield of the OMVs, reduce the toxicity and achieve the desired antigenic composition. Intravacc's OMV platform is scalable and allows rapid and efficient modification of the antigen composition, either through genetic modification of the bacterial host or by associating antigens with stored OMVs.

Watch the animation about Intravacc's Avacc® 10 intranasal COVID Vaccine

About Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global CDMO for infectious diseases and therapeutic vaccines. As an established independent CDMO with many years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology world-wide for many vaccines including polio, measles, DPT, Hib and influenza. Approximately 30% of childhood disease vaccines are based on Intravacc’s know-how and proprietary technology. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies for partners around the world, including biotech and pharmaceutical companies, governmental agencies and NGOs. With its innovative vaccine platforms OMV-VaccT, Cell-VaccT, Con-VaccT, E.co-VaccT and good manufacturing procedures (GMP) facilities the company is well positioned to address the unmet needs in the vaccine and immune therapy market.

Click here for the full article.

For more information, please visit www.intravacc.nl.

Contact info
Intravacc B.V.
Dr. Jan Groen, CEO
P: +31 30 7920 454

Sander Hagemans, Media relations
P: +31 30 7920 579
E: press.office@intravacc.nl

An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2c233c1-52f2-4670-921a-e0e4b097bf59

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Images

Tags

More Like This

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

Intravacc launches new website with a wealth of scientific knowledge to elevate vaccine innovation

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines

Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology

DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia